Avanos Medical (NYSE:AVNS) Issues FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.050-1.250 for the period, compared to the consensus earnings per share estimate of 1.670. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $713.1 million.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Stock Performance

NYSE AVNS opened at $15.72 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. Avanos Medical has a 1-year low of $14.40 and a 1-year high of $25.36. The firm has a market capitalization of $722.49 million, a P/E ratio of 46.24 and a beta of 0.98. The business’s 50-day simple moving average is $16.15 and its 200-day simple moving average is $19.73.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The business had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. Equities analysts predict that Avanos Medical will post 1.32 EPS for the current year.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.